-
State of New Product Development
（263KB）
- The information on this page is not intended to promote or advertise Tanabe Pharma products, or to recommend off-label or unapproved use of any product.
- If the product is being developed in multiple countries, including the US, "Global" is indicated in "Region/Country".
- When "Region/Country" is "Global", the most advanced stage of development among all regions/countries is indicated.
- If the "Stage" is filed and after, "Region/Country" is, in principle, Japan, the US, Europe, China, and Asia (excluding Japan and China). And not all region/countries are listed.
|
Development code Product name (Generic name) |
Mechanism |
Indications |
Region/ Country |
Stage |
Origin/Licensee |
|
MT-210 (Roluperidone) |
5-HT2A/Sigma2 receptor antagonist |
Schizophrenia |
US |
Filed |
Licensed to Minerva Neurosciences (US) |
|
Europe |
Phase 3 |
||||
|
ND0612 (Levodopa/Carbidopa) |
Continuous SC pump |
Parkinson's disease |
Global |
Phase 3 |
In-house |
|
US |
Filed |
||||
|
Europe |
Filed |
||||
|
MT-1186 Radicava ORS (US) (Edaravone) |
Free radical scavenger (Oral suspension) |
Amyotrophic lateral sclerosis: ALS |
Korea |
Filed |
In-house |
|
MT-0551 Uplizna (Inebilizumab) |
Humanized anti-CD19 monoclonal antibody |
Myasthenia gravis |
Japan |
Filed |
Licensed from Amgen (US) and co-developed |
|
MT-3921 (Unasnemab) |
Anti-RGMa antibody |
Spinal cord injury |
Global |
Phase 2 |
Co-discovered with Osaka University (Japan) |
|
HTLV-1 associated myelopathy |
Japan |
Phase 1 |
|
Development code Product name (Generic name) |
Mechanism |
Indications |
Region/ Country |
Stage |
Origin/Licensee |
|
MT-0551 Uplizna (Inebilizumab) |
Humanized anti-CD19 monoclonal antibody |
IgG4-related disease |
Japan |
Filed |
Licensed from Amgen (US) and co-developed |
|
Systemic sclerosis |
Japan |
Phase ３ |
Licensed from Amgen (US) |
||
|
MT-7117 (Dersimelagon) |
Selective melanocortin 1 receptor agonist |
Erythropoietic protoporphyria, X-Linked protoporphyria |
Global |
Phase ３ |
In-house |
|
Systemic sclerosis |
Global |
Phase 2 |
In-house |
||
|
MT-2990 |
Fully human anti-interleukin-33 (IL-33) monoclonal antibody |
ANCA associated vasculitis |
Japan |
Phase 1 |
Co-discovered with Pharma Foods International (Japan) |
|
MT-3534 |
Antibody |
Autoimmune disease |
Japan |
Phase 1 |
|
Development code Product name (Generic name) |
Mechanism |
Indications |
Region/ Country |
Stage |
Origin/Licensee |
|
MT-2111 (Loncastuximab tesirine) |
Anti-CD19 antibody drug conjugate |
Relapsed/Refractory diffuse large B-cell lymphoma (monotherapy) |
Japan |
Phase 1/2 |
Licensed from ADC Therapeutics (Switzerland) |
|
Relapsed/Refractory diffuse large B-cell lymphoma (with rituximab) |
Japan |
Phase 3 |
Licensed from ADC Therapeutics (Switzerland) and co-developed (Global study ongoing) |
||
|
MT-4561 |
BRD4 degraders |
Advanced solid tumors |
Global |
Phase 1/2 |
In-house |
|
Development code Product name (Generic name) |
Mechanism |
Indications |
Region/ Country |
Stage |
Origin/Licensee |
|
MT-2412 CANALIA (teneligliptin, canagliflozin) |
Fixed-dose combination of DPP-4 inhibitor and SGLT2 inhibitor |
Type 2 diabetes mellitus |
Asia |
Filed |
In-house |